The M&A Pool Set to Accelerate Biotech Innovation
Apr 03, 2024•14 min•Season 2Ep. 23
Episode description
Q1 2024 saw a handful of IPOs in the biotech sector, and mounting excitement over novel treatments. But there are less obvious trends in play, including a shift in focus by potential buyers in pharma. RBC’s biotech investment banking team analyzes deal activity in the year to date and what it signals for the sector’s future.
For the best experience, listen in Metacast app for iOS or Android
